Filing Flows › Schrodinger (SDGR) › Q3 2026
Schrodinger (SDGR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Schrodinger (SDGR) reported revenue of $64.5M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +10% from the quarter before. Operating margin was -40.5%, net loss $37.7M (58.5% of revenue).
Schrodinger, Q3 2026: revenue $64.5M (+19% year over year), operating margin -40.5%, net loss $37.7M, operating cash flow −$47.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $64.5M | +10% | +19% |
| Operating profit | −$26.1M | — | — |
| Net earnings | −$37.7M | -731% | — |
| Operating cash flow | −$47.6M | — | — |
What changed
Revenue was $64.5M in Q3 2026, up 19% year over year and up 10% from the previous quarter. Drug discovery was the largest line at 38% of revenue. Drug discovery added $11.2M year over year (up 86%), 110% of the total change. Contribution declined 60%.
Gross margin was 59.3%, up 7.7 points from Q3 2025. Operating costs exceeded revenue by $26.1M, an operating margin of -40.5%. Operating expenses fell 13% while revenue rose 19%. The quarter ended with a net loss of $37.7M, after a profit of $6.0M the previous quarter.
Operating cash flow was −$47.6M. Non-cash charges added back $1.5M of depreciation and amortization and $7.9M of share-based compensation. Working capital and other items used $19.3M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$48.9M.
Questions
What was Schrodinger's revenue in the third quarter 2026?
Schrodinger (SDGR) reported revenue of $64.5M for the third quarter 2026 (Q3 2026), +19% from a year earlier and +10% from the quarter before.
Was Schrodinger profitable in the third quarter 2026?
Operating loss was $26.1M (-40.5% of revenue) and net loss $37.7M.
Source: Schrodinger 10-Q on SEC EDGAR.